DOI:

A visible role for EAPCI at ESC Annual Congress 2008

William Wijns1*, MD, PhD, FESC, President EAPCI; Carlo di Mario2, MD, PhD, FESC, President-Elect EAPCI

People are always saying that there are too many congresses in every branch of medicine and perhaps this is true, all the more reason that the European Association of Percutaneous Cardiovascular Interventions (EAPCI), which is not in favour of excess, plays an active role in ensuring what does exist is of the greatest value to those attending. The EAPCI supports and endorses the scientific sessions of the various national interventional cardiology groups in different European countries, as well as specific meetings dedicated to fellows-in-training in interventional cardiology (a list is available on our website at www.escardio.org/
communities/EAPCI).

However, we play a different role in the annual subspecialty course on interventional cardiology which is EuroPCR, our official meeting as well at the annual congress of our mother society, the European Society of Cardiology (ESC). Here, our involvement is active and deep, shaping the essence of the meeting schedule itself. Having just returned from EuroPCR in Barcelona, we now turn our preparations to the ESC congress in Munich. Delegates from the EAPCI, who also sit on the scientific organising committee of the ESC congress directed by Fausto Pinto (chairman for the next 2 years), will soon begin the first steps towards 2009 congress preparation. Discussing how to insure that the ESC annual congress remains at the most exacting level of quality in its scientific medical and educational programme – a fact, witnessed by the increasing number of participants worldwide in this annual event. Obviously education and communication in our field is a continuous process and the EAPCI is playing an increasingly visible role.

We have highlighted below a number of sessions of particular interest at this year’s ESC Munich annual meeting – with its emphasis on coronary imaging. Visit www.escardio.org/CONGRESSES/ESC2008 for more information.

Hot Line II: recently completed clinical trials in interventional cardiology

Monday 1 September, 11:00 - 12:30 – Room Munich, Zone A4

The Hot line Session II chaired by Prof. P. Widimsky and Dr. W. Wijns will be of particular interest for interventional cardiologists. The one year results of the SYNTAX (Synergy between Percutaneous Coronary Intervention and Cardiac Surgery) trial will be presented by the principal investigators of this 3,075 patient trial, the interventional cardiologist Prof. P.W. Serruys and the cardiac surgeon Prof. F.W. Mohr. Comparing CABG and PCI using drug eluting stents in patients with three-vessel and left main stem disease, the results will, hopefully, put years of debate between surgeons and interventionalists on a new footing, providing much awaited data on what is the best revascularisation treatment for patients with left main stem and multivessel disease.

In the same session other clinical trials will be presented:

– CARDIa, a randomised trial of bypass surgery versus angioplasty in diabetic patients, a 600 patient trial from the UK and Ireland, whose results complement SYNTAX, though on a smaller scale.

– LEADERS, the one year results of a study which is a randomised comparison of a biolimus-A9 eluting stent with a sirolimus-eluting stent in all-comers, without the strict inclusion criteria which have limited the applicability of the results of most DES studies to current clinical practice.

For those of you interested in hearing more information from the SYNTAX trial, you will have the opportunity to “Meet the Trialists” and interact directly with the presenters of this trial.

ESC Andreas Gruentzig Lecture on Interventional Cardiology

Sunday 31 August, 14:00-15:30 – Rome - Zone C

This year’s ESC Gruentzig lecture will be chaired by Prof. M. Tendera and Prof. M. Komajda. It will feature a presentation by Dr. R. Virmani on how preclinical biocompatibility studies in various animal models help predict human responses to intravascular devices.

Other sessions of interest include:

Cardiac Anatomy for Interventional Cardiologists

Sunday 31 August, 10:00 - 12:30 – Cardiac Anatomy, Zone B4

Association Track (Focus Session) – The best of EuroPCR08

Sunday 31 August, 08:30-10:00 – Room London, Zone B4

And new this year, an interactive Session on

“Everything you always wanted to know about myocardial infarction and were afraid to ask”

Tuesday 2 September, 10:15 - 10:45 – Room Algiers, Zone C

EAPCI General Assembly

Monday 1 September, 15:30 - 16:30 – Room 11, Level 1, Zone C

This will be the occasion for us to report on recent activities and new initiatives with special focus on interventional training, as well as the perfect opportunity for you to show your support and positive suggestions. The modalities for next year’s election will also be announced.

To find out more about EAPCI, to learn about the EAPCI Membership Programme or gather information on next year’s interventional fellowships, as well as on other sessions of interest during the Munich meeting, please come and meet us at one of our stands, located in Zone B2 or at the ESC Membership Stand, Zone C or all year round at www.escardio.org/communities/EAPCI.

Volume 4 Number 2
Aug 20, 2008
Volume 4 Number 2
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00479 Jun 1, 2026
Valve thrombosis or valve deterioration: what truly drives the prognosis?
Waksman R and Phichaphop A
free

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al

Original Research

10.4244/EIJ-D-25-01268 Jun 1, 2026
Early outcomes of redo-TAVI with the SAPIEN 3 platform: the prospective, multicentre ReTAVI registry
Tarantini G et al

Research Correspondence

10.4244/EIJ-D-25-01160 Jun 1, 2026
First-in-human experience with a heterotopic cross-caval transcatheter tricuspid valve replacement
Estevez-Loureiro R et al

Original Research

10.4244/EIJ-D-26-00416 May 21, 2026
Long-term clinical outcomes of high-risk plaques with negative fractional flow reserve: the PECTUS-obs study
Volleberg R et al
Trending articles
87.2

State-of-the-Art

10.4244/EIJ-D-25-00266 Jan 19, 2026
Lesion stratification with intracoronary imaging
McGarvey M et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
34.8

Original Research

10.4244/EIJ-D-25-01006 Mar 16, 2026
Clinical outcomes and haemodynamic response after blinded stress assessment of moderate aortic stenosis
Eerdekens R et al
22.2

Viewpoint

10.4244/EIJ-D-25-01066 May 4, 2026
Intracoronary imaging guidance for de novo coronary lesion treatment with drug-coated balloons
Amabile N et al
free
20.75

Flashlight

10.4244/EIJ-D-25-01014 Apr 6, 2026
Stent retriever-assisted coronary thrombectomy with continuous aspiration
Liabot Q et al
open access
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
19

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved